ABSTRACT

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a potentially fatal agent for a new emerging viral disease (COVID-19) is of great global public health emergency. Herein, we represented potential antibody-based treatments especially monoclonal antibodies (mAbs) that may exert a potential role in treatment as well as developing vaccination strategies against COVID-19.

Areas covered: We used PubMed, Google Scholar, and clinicaltrials.gov search strategies for relevant papers. We demonstrated some agents with potentially favorable efficacy as well as favorable safety. Several therapies are under assessment to evaluate their efficacy and safety for COVID19. However, the development of different strategies such as SARS-CoV-2-based vaccines and antibody therapy are urgently required beside other effective therapies such as plasma, anticoagulants, and immune as well as antiviral therapies. We encourage giving more attention to antibody-based treatments as an immediate strategy. Although there has not been any approved specific vaccine until now, developing vaccination strategies may have a protective effect against COVID-19.

Expert opinion: An antiviral mAbs could be a safe and high-quality therapeutic intervention which is greatly recommended for COVID-19. Additionally, the high sequence homology between the SARS-CoV-2 and SARS/MERS viruses could shed light on developing to design a vaccine against SARS-CoV-2.

摘要

简介：严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 作为一种新出现的病毒性疾病 (COVID-19) 的潜在致命病原体，是全球重大的突发公共卫生事件。在此，我们代表了潜在的基于抗体的治疗，尤其是单克隆抗体 (mAb)，它们可能在治疗以及开发针对 COVID-19 的疫苗接种策略中发挥潜在作用。

涵盖的领域：我们使用 PubMed、Google Scholar 和 Clinicaltrials.gov 搜索相关论文的策略。我们展示了一些具有潜在良好疗效和良好安全性的药物。正在评估几种疗法，以评估其对 COVID19 的疗效和安全性。然而，除了血浆、抗凝剂、免疫和抗病毒疗法等其他有效疗法外，还迫切需要开发基于 SARS-CoV-2 的疫苗和抗体疗法等不同策略。我们鼓励将更多关注基于抗体的治疗作为一种直接策略。尽管到目前为止还没有任何获批的特定疫苗，但制定疫苗接种策略可能对 COVID-19 具有保护作用。

专家意见：抗病毒单克隆抗体可能是一种安全且高质量的治疗干预措施，强烈推荐用于 COVID-19。此外，SARS-CoV-2 和 SARS/MERS 病毒之间的高序列同源性可能有助于开发针对 SARS-CoV-2 的疫苗。